Long-acting basal insulin analogues (insulin glargine U100, insulin detemir) significantly improved diabetes management, providing longer duration, flatter profiles of action, lower risk of hypoglycemia, and less glycemic variability compared to NPH (Neutral Protamine Hagedorn) insulin [7,8]. The gene discussed is INS; the disease is diabetes mellitus.